Development of lexatumumab in combination with temsirolimus against advanced renal cell carcinoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592395
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Hyogo Medical University (2013-2014); Kagawa University (2012)
• Principal Investigator: WU XIUXIAN 兵庫医科大学, 医学部, 講師 (10346645)
• Co-Investigator(Kenkyū-buntansha): SUZUKI Toru 兵庫医科大学, 医学部, 講師 (00441296) ; KANEMATSU Akihiro 兵庫医科大学, 医学部, 准教授 (90437202) ; YAMAMO Shingo 兵庫医科大学, 医学部, 教授 (80322741)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: lexatumumab / TRAIL-R2 / 腎癌細胞 / テムシロリムス / mapatumumab / TRAIL-R1 / apoptosis

Outline of Final Research Achievements

Development of anti-TRAIL receptor antibody in combination with temsirolimus against advanced renal cell carcinoma was performed. We found: (1) anti-TRAIL death receptor 2 antibody lexatumumab in combination with a new molecular targeted drug temsirolimus had an additive cytotoxic effect, although there was no a synergistic effect; (2) anti-TRAIL death receptor 1 antibody mapatumumab in combination with clinically achievable concentrations of epirubicin or pirarubicin had a synergistic cytotoxic effect; the synergistic effect was due to apoptosis via activation of the caspase cascades; (3) mapatumumab in combination with a protein inhibitor anisomycin had a synergistic cytotoxic effect.

Free Research Field

医歯薬学